Post-MPN-AML indicates post-MPN transformation to AML; NF, mutations not found in small patient cohorts; and NK, mutation frequencies not known.

* MPNs that are JAK2V617F positive often transform to JAK2V617F-negative AML.

† Higher frequency reported in JAK2-unmutated idiopathic erythrocytosis.

‡ Mutations in CALR correlate with improved survival in MF and a reduced incidence of thrombosis in ET.

§ Mutations in ASXL1, EZH2, IDH1/2, and SRSF2 correlate with poorer outcome in MF in terms of leukemia-free and overall survival.

‖ Mutations in SRSF2 and TP53 correlate with poorer outcome in post-MPN AML.